Celastramycin A
目录号 : GC14356An antibacterial and immunosuppressant
Cas No.:491600-94-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Celastramycin A is an antibiotic that inhibits the growth of bacteria and mycobacteria and is also a potent innate immune suppressor [1][2].
Celastramycin A is a benzoyl pyrrole-type compound isolated from endophytic bacteria Streptomyces MaB-QuH-8 living in plants of the Celastraceae family. Celastramycin A exhibited high activity against a series of multiresistent bacteria and mycobacteria [1]. Celastramycin A inhibited the growth of Gram-positive bacteria and mycobacteria with minimal inhibitory concentration (MIC) as low as 0.05 μg/ml [1]. In the ex vivo Drosophila culture system, Celastramycin A showed a potent immunosuppressive effect with IC50 value of 0.008 μg/mL. In human umbilical vein endothelial cells (HUVECs), Celastramycin A potently inhibited the production of IL-8 with IC50 value of 0.06 μg/mL. So Celastramycin A could be used as a lead compound for novel immunosuppressive agents [2].
References:
[1]. Pullen C, Schmitz P, Meurer K, et al. New and bioactive compounds from Streptomyces strains residing in the wood of Celastraceae. Planta. 2002 Nov;216(1):162-7.
[2]. Kikuchi H, Sekiya M, Katou Y, et al. Revised structure and synthesis of celastramycin a, a potent innate immune suppressor. Org Lett. 2009 Apr 16;11(8):1693-5.
| Cas No. | 491600-94-3 | SDF | |
| 化学名 | (3-chloro-5-hexyl-2,6-dihydroxyphenyl)(4,5-dichloro-1H-pyrrol-3-yl)-methanone | ||
| Canonical SMILES | ClC1=CC(CCCCCC)=C(O)C(C(C2=CC(Cl)=C(Cl)N2)=O)=C1O | ||
| 分子式 | C17H18Cl3NO3 | 分子量 | 390.7 |
| 溶解度 | ≤20mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5595 mL | 12.7975 mL | 25.5951 mL |
| 5 mM | 0.5119 mL | 2.5595 mL | 5.119 mL |
| 10 mM | 0.256 mL | 1.2798 mL | 2.5595 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。